Welcome to our dedicated page for Mira Pharma SEC filings (Ticker: MIRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) SEC filings page provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents detail material events, clinical and regulatory milestones, capital-raising activities, and corporate governance decisions for this Florida-incorporated, Miami-based clinical-stage biopharmaceutical company.
Through MIRA’s Forms 8-K, users can review key developments in the Ketamir-2 program, including FDA clearance of the Investigational New Drug (IND) application for neuropathic pain, favorable topline data from the single ascending dose Phase 1 study, and initiation of the multiple ascending dose portion with chemotherapy-induced peripheral neuropathy selected as the lead Phase 2a indication. Filings also summarize preclinical evidence, DEA determinations that Ketamir-2 is not a controlled substance, and its selective NMDA receptor targeting profile.
Filings further describe MIRA-55, an oral THC or marijuana analog with preclinical results in inflammatory and nociceptive pain, and the company’s intention to pursue an IND for chronic inflammatory pain. The completed acquisition of SKNY Pharmaceuticals, Inc. and addition of SKNY-1 for obesity and smoking cessation are documented in a Form 8-K, which also notes SKNY’s contribution of marketable securities and the resulting multi-program pipeline.
Investors can also examine capital markets and governance disclosures, such as at-the-market equity offerings, Nasdaq listing compliance updates, equity incentive plan amendments, shareholder voting results, and executive compensation and incentive awards tied to development, acquisition, and market capitalization milestones. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand clinical updates, transaction terms, and other material information contained in MIRA’s 8-Ks and related filings.